The Biotech Growth Trust PLC
|Vertex Pharmaceuticals Inc||6.91 %|
|Neurocrine Biosciences Inc||5.69 %|
|Biogen Inc||5.37 %|
|Mirati Therapeutics Inc||5.25 %|
|Amgen Inc||4.32 %|
|Gilead Sciences Inc||4.00 %|
|Applied Therapeutics Inc||3.67 %|
|CRISPR Therapeutics AG||3.50 %|
|CanSino Biologics Inc Class H||3.30 %|
|Deciphera Pharmaceuticals Inc||3.27 %|
|United States||78.04 %|
|Asia - Emerging||7.40 %|
Klemm joined OrbiMed in 2000 as a biotechnology analyst. Klemm has earned the right to use the Chartered Financial Analyst designation.
Hsu joined OrbiMed in 2002 as a biotechnology analyst. Prior to joining OrbiMed, he worked as a financial analyst in the healthcare investment banking group at Lehman Brothers. Hsu has earned the right to use the Chartered Financial Analyst designation.
Data provided by Morningstar.
The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Money Observer and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.
This information is sourced from our partner Morningstar. We believe the data to be correct however you should take care in using any information.
You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.